中国药业
中國藥業
중국약업
CHINA PHARMACEUTICALS
2015年
10期
51-52
,共2页
阿托伐他汀%丹参川芎嗪%颈动脉粥样硬化%血脂
阿託伐他汀%丹參川芎嗪%頸動脈粥樣硬化%血脂
아탁벌타정%단삼천궁진%경동맥죽양경화%혈지
atorvastatin%salviae miltiorrhizae and ligustrazine%carotid atherosclerosis%blood lipid
目的：探讨阿托伐他汀联合丹参川芎嗪治疗高胆固醇血症并冠状动脉粥样硬化性心脏病（简称冠心病）对颈动脉粥样硬化斑块的影响。方法将126例患者随机分成观察组和对照组，各63例。对照组患者给予阿托伐他汀治疗，观察组患者在此基础上加用丹参川芎嗪联合治疗。比较两组患者内-中膜厚度、斑块面积、血脂变化及并发症情况。结果治疗后观察组患者的内-中膜厚度与斑块面积分别为（0.74±0.04）mm和（0.76±0.11）cm2，显著小于对照组的（0.93±0.05）mm和（0.98±0.13）cm2（ P﹤0.05）。治疗后观察组患者血清总胆固醇（TC）、三酰甘油（TG）、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）、载脂蛋白A（apoA）、载脂蛋白B （apoB）与脂蛋白 A（LPA）的体内水平均显著优于对照组（ P﹤0.05）。观察组患者短暂性脑缺血发作（TIA）与复发的发生率分别为4.76%和9.52%，均显著低于对照组的15.87%和23.81%（ P﹤0.05）。结论阿托伐他汀联合丹参川芎嗪治疗高胆固醇血症并冠心病患者颈动脉粥样硬化斑块疗效确切，安全性好，值得临床推广。
目的：探討阿託伐他汀聯閤丹參川芎嗪治療高膽固醇血癥併冠狀動脈粥樣硬化性心髒病（簡稱冠心病）對頸動脈粥樣硬化斑塊的影響。方法將126例患者隨機分成觀察組和對照組，各63例。對照組患者給予阿託伐他汀治療，觀察組患者在此基礎上加用丹參川芎嗪聯閤治療。比較兩組患者內-中膜厚度、斑塊麵積、血脂變化及併髮癥情況。結果治療後觀察組患者的內-中膜厚度與斑塊麵積分彆為（0.74±0.04）mm和（0.76±0.11）cm2，顯著小于對照組的（0.93±0.05）mm和（0.98±0.13）cm2（ P﹤0.05）。治療後觀察組患者血清總膽固醇（TC）、三酰甘油（TG）、低密度脂蛋白膽固醇（LDL-C）、高密度脂蛋白膽固醇（HDL-C）、載脂蛋白A（apoA）、載脂蛋白B （apoB）與脂蛋白 A（LPA）的體內水平均顯著優于對照組（ P﹤0.05）。觀察組患者短暫性腦缺血髮作（TIA）與複髮的髮生率分彆為4.76%和9.52%，均顯著低于對照組的15.87%和23.81%（ P﹤0.05）。結論阿託伐他汀聯閤丹參川芎嗪治療高膽固醇血癥併冠心病患者頸動脈粥樣硬化斑塊療效確切，安全性好，值得臨床推廣。
목적：탐토아탁벌타정연합단삼천궁진치료고담고순혈증병관상동맥죽양경화성심장병（간칭관심병）대경동맥죽양경화반괴적영향。방법장126례환자수궤분성관찰조화대조조，각63례。대조조환자급여아탁벌타정치료，관찰조환자재차기출상가용단삼천궁진연합치료。비교량조환자내-중막후도、반괴면적、혈지변화급병발증정황。결과치료후관찰조환자적내-중막후도여반괴면적분별위（0.74±0.04）mm화（0.76±0.11）cm2，현저소우대조조적（0.93±0.05）mm화（0.98±0.13）cm2（ P﹤0.05）。치료후관찰조환자혈청총담고순（TC）、삼선감유（TG）、저밀도지단백담고순（LDL-C）、고밀도지단백담고순（HDL-C）、재지단백A（apoA）、재지단백B （apoB）여지단백 A（LPA）적체내수평균현저우우대조조（ P﹤0.05）。관찰조환자단잠성뇌결혈발작（TIA）여복발적발생솔분별위4.76%화9.52%，균현저저우대조조적15.87%화23.81%（ P﹤0.05）。결론아탁벌타정연합단삼천궁진치료고담고순혈증병관심병환자경동맥죽양경화반괴료효학절，안전성호，치득림상추엄。
Objective To investigate the effect of atorvastatin combined with salviae miltiorrhizae and ligustrazine for treating carotid atherosclerotic plaques in the patients with cholesterolemia complicating coronary atherosclerosis heart disease. Methods Totally 126 pa-tients with cholesterolemia complicating coronary atherosclerosis heart disease were randomly divided into the observed group(63 cases) and the control group(63 cases). The control group was treated with atorvastatin,while on this basis the observed group was added with salviae miltiorrhizae and ligustrazine. The intima-media thickness(IMT),plaque area,blood lipid changes and complications were com-pared between the two groups. Results The IMT and plaque area after treatment in the observation group were(0. 74 ± 0. 04)mm and (0. 76 ± 0. 11)cm2,which were significantly lower than(0. 93 ± 0. 05)mm and(0. 98 ± 0. 13)cm2 in the control group( P ﹤ 0. 05). The levels of TC,TG,LDL-C,HDL-C,apoA,apoB and LPA after treatment in the observation group were significantly better than those in the control group( P ﹤ 0. 05). The occurrence rates of transient ischemia attack(TIA) and recurrence in the observation group were 4. 76% and 9. 52% respectively,which were significantly lower than 15. 87% and 23. 81% in the control group( P ﹤ 0. 05). Conclusion Atorvastatin combined with salviae miltiorrhizae and ligustrazine has definite effect and good safety for treating carotid atherosclerotic plaques in the patients with acute ischemic stroke and is worthy of clinical promotion.
